Abstract | PURPOSE: METHODS: 126 patients were recruited this cohort study consecutively, and CD155 expression on tumor cells was detected by immunohistochemistry. The Kaplan-Meier survival curve and Cox hazard regression model were used to estimate the association. RESULTS: 38.1% patients had an overexpression of CD155, and the proportion of tumor cells with CD155 overexpression was 17%, 39%, 37%, and 62% among Luminal A, Luminal B, HER2-positive, and triple negative breast cancer cases, respectively (p < 0.05). Patients with CD155 overexpression had the Ki-67 index significantly higher than that of patients with low expression (42% vs. 26%). Though the number of tumor-infiltrating lymphocytes was higher among patients with CD155 overexpression (144/HPF vs. 95/HPF), the number of PD-1+ lymphocytes was significantly higher (52/HPF vs. 25/HPF, p < 0.05). Patients of CD155 overexpression had the disease-free and overall survival decreased by 13 months and 9 months, respectively (p < 0.05). CD155 overexpression was associated with an increased relapse (HR = 13.93, 95% CI 2.82, 68.91) and death risk for breast cancer patients (HR = 5.47, 1.42, 20.99). CONCLUSIONS: Overexpression of CD155 was correlated with more proliferative cancer cells and a dysfunctional immune microenvironment. CD155 overexpression introduced a worse relapse-free and overall survival and might be a potential immunotherapy target for breast cancer.
|
Authors | Yu-Chen Li, Quan Zhou, Qing-Kun Song, Rui-Bin Wang, Shuzhen Lyu, Xiudong Guan, Yan-Jie Zhao, Jiang-Ping Wu |
Journal | Journal of immunology research
(J Immunol Res)
Vol. 2020
Pg. 3948928
( 2020)
ISSN: 2314-7156 [Electronic] Egypt |
PMID | 32411795
(Publication Type: Journal Article)
|
Copyright | Copyright © 2020 Yu-Chen Li et al. |
Chemical References |
- Biomarkers, Tumor
- Immune Checkpoint Inhibitors
- PDCD1 protein, human
- Programmed Cell Death 1 Receptor
- Receptors, Virus
- poliovirus receptor
|
Topics |
- Biomarkers, Tumor
(analysis, immunology, metabolism)
- Breast
(immunology, pathology)
- Breast Neoplasms
(immunology, metabolism, mortality, therapy)
- Cell Proliferation
- Chemotherapy, Adjuvant
(methods)
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Immune Checkpoint Inhibitors
(pharmacology, therapeutic use)
- Immunohistochemistry
- Kaplan-Meier Estimate
- Lymphocytes, Tumor-Infiltrating
(immunology)
- Mastectomy
- Neoplasm Recurrence, Local
(epidemiology, immunology, prevention & control)
- Prognosis
- Programmed Cell Death 1 Receptor
(analysis, immunology, metabolism)
- Receptors, Virus
(analysis, antagonists & inhibitors, immunology, metabolism)
- Tumor Microenvironment
(immunology)
|